Colorectal tumors are effectively eradicated by combined inhibition of β-catenin, KRAS, and the oncogenic transcription factor ITF2

Cancer Research

Volumn 70, Issue 18, 2010, Pages 7253-7263

  Mologni, Luca ^a   Dekhil, Hafedh ^b   Ceccon, Monica ^a   Purgante, Stefania ^a   Lan, Cathy ^b   Cleris, Loredana ^c   Magistroni, Vera ^b   Formelli, Franca ^c   Gambacorti Passerini, Carlo B ^a,b  

^a SAN GERARDO HOSPITAL   (Italy)

^b MCGILL UNIVERSITY   (Canada)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DOXORUBICIN; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; SHORT HAIRPIN RNA; SURVIVIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ITF 2; UNCLASSIFIED DRUG; BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; CTNNB1 PROTEIN, MOUSE; DOXYCYCLINE; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN; SMALL INTERFERING RNA; TCF4 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; COLORECTAL TUMOR; CONTROLLED STUDY; DOWN REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE SRC; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HCT116 CELL LINE; METABOLISM; NUDE MOUSE; PATHOLOGY;

ANIMALS; APOPTOSIS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BETA CATENIN; COLORECTAL NEOPLASMS; DOWN-REGULATION; DOXYCYCLINE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; MICE; MICE, NUDE; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77956904030     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-1108     Document Type: Article

References (41)

1. Gambacorti-Passerini C. Part I: Milestones in personalised medicine-imatinib. Lancet Oncol 2008;9:600.
2. Polakis P. Wnt signaling and cancer. Genes Dev 2000;14:1837-51.
3. Gregorieff A, Clevers H. Wnt signaling in the intestinal epithelium: from endoderm to cancer. Genes Dev 2005;19:877-90.
4. Barker N. The canonical Wnt/β-catenin signalling pathway. Methods Mol Biol 2008;468:5-15.
5. Korinek V, Barker N, Morin PJ, et al. Constitutive transcriptional activation by a β-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997;275:1784-7.
6. van de Wetering M, Sancho E, Verweij C, et al. The β-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002;111:241-50.
7. Naishiro Y, Yamada T, Takaoka AS, et al. Restoration of epithelial cell polarity in a colorectal cancer cell line by suppression of β-catenin/T- cell factor 4-mediated gene transactivation. Cancer Res 2001;61:2751-8.
8. van de Wetering M, Oving I, Muncan V, et al. Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector. EMBO Rep 2003;4:609-15.
9. Verma UN, Surabhi RM, Schmaltieg A, Becerra C, Gaynor RB. Small interfering RNAs directed against β-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res 2003;9:1291-300.
10. Mariadason JM, Bordonaro M, Aslam F, et al. Down-regulation of β-catenin TCF signaling is linked to colonic epithelial cell differentiation. Cancer Res 2001;61:3465-71.
11. Massari ME, Murre C. Helix-loop-helix proteins: regulators of transcription in eucaryotic organisms. Mol Cell Biol 2000;20:429-40.
12. Henthorn P, McCarrick-Walmsley R, Kadesch T. Sequence of the cDNA encoding ITF-2, a positive-acting transcription factor. Nucleic Acids Res 1990;18:678. (Pubitemid 20064039)
13. Corneliussen B, Thornell A, Hallberg B, Grundstrom T. Helix-loop-helix transcriptional activators bind to a sequence in glucocorticoid response elements of retrovirus enhancers. J Virol 1991;65:6084-93.
14. Skerjanc IS, Truong J, Filion P, McBurney MW. A splice variant of the ITF-2 transcript encodes a transcription factor that inhibits MyoD activity. J Biol Chem 1996;271:3555-61.
15. Chen B, Lim RW. Physical and functional interactions between the transcriptional inhibitors Id3 and ITF-2b. Evidence toward a novel mechanism regulating muscle-specific gene expression. J Biol Chem 1997;272:2459-63.
16. Itahana Y, Piens M, Fong S, Singh J, Sumida T, Desprez PY. Expression of Id and ITF-2 genes in the mammary gland during pregnancy. Biochem Biophys Res Commun 2008;372:826-30.
17. Kolligs FT, Nieman MT, Winer I, et al. ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with β-catenin defects and promotes neoplastic transformation. Cancer Cell 2002;1:145-55.
18. Herbst A, Bommer GT, Kriegl L, et al. ITF-2 is disrupted via allelic loss of chromosome 18q21, and ITF-2B expression is lost at the adenoma-carcinoma transition. Gastroenterology 2009;137:639-48, 648 e631-39.
19. Frattini M, Balestra D, Suardi S, et al. Different genetic features associated with colon and rectal carcinogenesis. Clin Cancer Res 2004;10:4015-21.
20. Haigis KM, Kendall KR, Wang Y, et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 2008;40:600-8.
21. Janssen KP, Alberici P, Fsihi H, et al. APC, oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression. Gastroenterology 2006;131:1096-109.
22. Sansom OJ, Meniel V, Wilkins JA, et al. Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo. Proc Natl Acad Sci U S A 2006;103:14122-7.
23. Park KS, Jeon SH, Kim SE, et al. APC inhibits ERK pathway activation and cellular proliferation induced by RAS. J Cell Sci 2006;119:819-27.
24. Rao S, Cunningham D, de Gramont A, et al. Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol 2004;22:3950-7.
25. Friday BB, Adjei AA. K-ras as a target for cancer therapy. Biochim Biophys Acta 2005;1756:127-44.
26. Available from: http://www.sabiosciences.com.
27. Mologni L, Cleris L, Magistroni V, et al. Valproic acid enhances bosutinib cytotoxicity in colon cancer cells. Int J Cancer 2009;124:1990-6.
28. Chun JY, Hu Y, Pinder E, Wu J, Li F, Gao AC. Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter. Mol Cancer Ther 2007;6:2572-80.
29. Sala E, Mologni L, Truffa S, Gaetano C, Bollag GE, Gambacorti-Passerini C. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res 2008;6:751-9.
30. Lea MA, Ibeh C, Shah N, Moyer MP. Induction of differentiation of colon cancer cells by combined inhibition of kinases and histone deacetylase. Anticancer Res 2007;27:741-8.
31. Wolthuis RM, de Ruiter ND, Cool RH, Bos JL. Stimulation of gene induction and cell growth by the Ras effector Rlf. EMBO J 1997;16:6748-61.
32. Feig LA. Ral-GTPases: approaching their 15 minutes of fame. Trends Cell Biol 2003;13:419-25.
33. Kim SW, Hayashi M, Lo JF, Yang Y, Yoo JS, Lee JD. ADP-ribosylation factor 4 small GTPase mediates epidermal growth factor receptor-dependent phospholipase D2 activation. J Biol Chem 2003;278:2661-8.
34. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007;318:1108-13.
35. Tuveson DA, Shaw AT, Willis NA, et al. Endogenous oncogenic K-ras (G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 2004;5:375-87.
36. Scholl C, Frohling S, Dunn IF, et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009;137:821-34.
37. Lim KH, Baines AT, Fiordalisi JJ, et al. Activation of RalA is critical for Ras-induced tumorigenesis of human cells. Cancer Cell 2005;7:533-45.
38. Luo F, Brooks DG, Ye H, et al. Mutated K-ras(Asp12) promotes tumourigenesis in Apc(Min) mice more in the large than the small intestines, with synergistic effects between K-ras and Wnt pathways. Int J Exp Pathol 2009;90:558-74.
39. Law BK, Norgaard P, Moses HL. Farnesyltransferase inhibitor induces rapid growth arrest and blocks p70s6k activation by multiple stimuli. J Biol Chem 2000;275:10796-801.
40. Berg T. Small-molecule inhibitors of protein-protein interactions. Curr Opin Drug Discov Devel 2008;11:666-74.
41. Sharma SV, Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 2007;21:3214-31.